Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas

Journal:

Journal of Clinical Oncology

Published:

2025-07-25

DOI:

10.1200/jco-25-00363

Affiliations:

16

Authors:

15

Go to article

Institutions	Authors	Share
Boehringer Ingelheim Pharma GmbH & Co. KG, Germany	1.000000	0.07
National Cancer Center Hospital East, Japan	1.000000	0.07
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.07
Clínica Universidad de Navarra (CUN), UNAV, Spain	1.000000	0.07
Boehringer Ingelheim International GmbH, Germany	1.000000	0.07
Vall d'Hebron University Hospital (HUVH), ICS, Spain	1.000000	0.07
Biomedical Research Institute (INCLIVA), Spain	1.000000	0.07
University Hospital of Würzburg (UKW), JMU, Germany	1.000000	0.07
Boehringer Ingelheim Investment Co., Ltd., China	1.000000	0.07
Boehringer Ingelheim - France, France	1.000000	0.07
University Hospital of Cologne, Germany	1.000000	0.07
The Winship Cancer Institute of Emory University, United States of America (USA)	1.000000	0.07
UPMC Hillman Cancer Center (UPCI), United States of America (USA)	1.000000	0.07
National Center for Tumor Diseases Dresden (NCT Dresden), Germany	1.000000	0.07
Hospital del Mar Medical Research Institute (IMIM), Spain	0.500000	0.03
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain	0.500000	0.03

Interested in Oncology and Carcinogenesis?